Janssen Global Services, LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$6.6Mgeneral payments (2019-2025)
$29Kresearch payments (2019-2025)
1,007clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Carvykti $292K associated (2023-2025)
- Darzalex $262K associated (2023-2025)
- Tecvayli $235K associated (2023-2025)
- Tremfya $196K associated (2023-2025)
- Talvey $152K associated (2023-2025)
- Rybrevant $140K associated (2023-2025)
- Erleada $138K associated (2023-2025)
- Spravato $114K associated (2023-2025)
- Imbruvica $62K associated (2023-2025)
- Simponi $30K associated (2023-2025)
- Stelara $20K associated (2023-2025)
- Akeega $731 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Michael Fabrizio | Virginia Beach, VA | Urology | $350,909.68 |
| Jullian Cerasuolo | Chicago, IL | Optometrist | $324,438.81 |
| Mary Muoneke | Atlanta, GA | Nephrology (Internal Medicine) | $119,250.00 |
| Rafael Fonseca | Scottsdale, AZ | Hematology (Internal Medicine) | $109,183.18 |
| Stephen Freedland | West Hollywood, CA | Urology | $89,257.50 |
| Saad Usmani | Charlotte, NC | Internal Medicine | $74,904.76 |
| Neal Shore | Myrtle Beach, SC | Urology | $58,505.64 |
| Faith Davies | New York, NY | Hematology (Internal Medicine) | $56,074.62 |
| Yi Lin | Rochester, MN | Hematology (Internal Medicine) | $52,307.67 |
| James Krueger | New York, NY | Dermatology | $45,683.57 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.